Recurrent or primary metastatic cervical cancer: current and future treatments
Authors:
Top Cited Papers
Open Access
- 13 September 2022
- Vol. 7 (5) , 100579
Abstract
No abstract availableKeywords
Funding Information
- Roche
- AstraZeneca
- AbbVie
- GlaxoSmithKline
- Merck Sharp and Dohme United Kingdom
- Bristol-Myers Squibb
- Daiichi-Sankyo
- Pfizer
- MedImmune
- Novartis
- Ipsen
This publication has 88 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- Tim-3 Expression in Cervical Cancer Promotes Tumor MetastasisPLOS ONE, 2013
- Dysregulated Expression of Both the Costimulatory CD28 and Inhibitory CTLA-4 Molecules in PB T Cells of Advanced Cervical Cancer Patients Suggests Systemic Immunosuppression Related to Disease ProgressionPathology and Oncology Research, 2011
- Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: A Gynecologic Oncology Group studyGynecologic Oncology, 2011
- Tissue Factor, Blood Coagulation, and Beyond: An OverviewInternational Journal of Inflammation, 2011
- A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4+FOXP3+ regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervixCellular & Molecular Immunology, 2010
- Phase II, Open-Label Study of Pazopanib or Lapatinib Monotherapy Compared With Pazopanib Plus Lapatinib Combination Therapy in Patients With Advanced and Recurrent Cervical CancerJournal of Clinical Oncology, 2010
- Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2009
- A Phase II Trial of Erlotinib in Recurrent Squamous Cell Carcinoma of the CervixInternational Journal of Gynecological Cancer, 2009
- Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicityReviews in Medical Virology, 2005